This week, the U.S. Senate Health, Education, Labor & Pensions (HELP) Committee considers legislation that would lower choice in the market by creating a one-size-fits all pharmacy benefit contracting model for health plans and employers. As Congress considers mandating contracting
In case you missed it, a new article in Inside Health Policy reported that “Investors for eight major drug companies will vote throughout the spring on 11 proposals aimed at reducing the use of common drug patent practices and pharmaceutical lobbying activities
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), discusses the root cause of high drug prices – big drug companies’ anti-competitive tactics used to keep more affordable prescription drugs from entering
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the final Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs rule: “PCMA applauds CMS for delaying the
Between January 2022 and January 2023, the total number of independent pharmacies nationwide increased by 99, a 0.4% increase. Looking at the new five-year trend, the number of independent pharmacies has increased by 0.5%. Overall, the 2023 pharmacy counts have
Pharmacy Direct and Indirect Remuneration (DIR) Value-based Pharmacy Reimbursement Reduces Drug Costs for Medicare Beneficiaries, Lowers Spending. Pharmacy direct and indirect remuneration, or Pharmacy DIR, is a form of value-based contracting in Medicare Part D. Pharmacy DIR increases the quality
PBMs Reduce Insulin Costs PBMs are working to improve the lives of patients living with diabetes and their families Insulin prices are high because there are only a few insulin manufacturers, shielded from competition, and those companies set and raise
Unlocking an Affordable Future Unlocking an Affordable Future NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics Stop The
Pharmacy Benefit Companies Negotiate with Big Drug Companies to Lower Prescription Drug Costs for Patients and Families Last week, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing, “The Need to Make Insulin Affordable for All Americans,”
©2024 PCMA. All Rights Reserved.
